Skip to main content
SpringerLink
Log in

Kombinationstherapie mit AT1-Antagonist plus Kalziumantagonist bei nierenkranken Patienten

Combination therapy with angiotensin II receptor blocker plus calcium channel blocker for patients with kidney disease

  • Für Sie gelesen
  • Published:
Der Nephrologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bakris GL, Sarafidis PA, Weir MR et al (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375:1173–1181

    Article  PubMed  CAS  Google Scholar 

  2. Briasoulis A, Bakris GL (2013) The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int 83:20–22

    Article  PubMed  CAS  Google Scholar 

  3. National Institute for Health and Clinical Excellence (2011) Hypertension: Clinical management of primary hypertension in adults. http://publications.nice.org.uk/hypertension-cg127

  4. Jamerson K, Weber MA, Bakris GL et al (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417–2428

    Article  PubMed  CAS  Google Scholar 

  5. Kim-Mitsuyama S, Ogawa H, Matsui K et al (2013) An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int 83:167–176

    Article  PubMed  CAS  Google Scholar 

  6. (o A) (2009) Retraction – Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 374:1226

    Google Scholar 

  7. Ogawa H, Kim-Mitsuyama S, Matsui K et al (2012) Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med 125:981–990

    Article  PubMed  CAS  Google Scholar 

  8. Parving HH, Brenner BM, McMurray JJ et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204–2213

    Article  PubMed  CAS  Google Scholar 

  9. Yusuf S, Teo KK, Pogue J et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seinen Koautoren an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. III. Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    S. Frerk &  U. Wenzel

Authors
  1. S. Frerk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Wenzel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frerk, S., Wenzel, U. Kombinationstherapie mit AT1-Antagonist plus Kalziumantagonist bei nierenkranken Patienten. Nephrologe 8, 167–168 (2013). https://doi.org/10.1007/s11560-013-0747-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-013-0747-y

Search

Navigation